Table 1

ID93/GLA-SE–induced protection against TB and MDR-TB.

Vaccines*LungSpleen
CFU (log10)ReductionCFU (log10)Reduction
H37Rv
Saline5.99 ± 0.255.46 ± 0.61
GLA-SE6.05 ± 0.29−0.065.17 ± 0.570.29
ID93/GLA-SE5.52 ± 0.18§∥0.484.72 ± 0.35§0.74
BCG5.07 ± 0.44§0.924.02 ± 0.60§1.43
TN5904
Saline5.63 ± 0.175.17 ± 0.42
GLA-SE5.58 ± 0.190.054.91 ± 0.730.26
ID93/GLA-SE5.11 ± 0.26§0.524.90 ± 0.40 0.27
BCG4.42 ± 0.27§1.203.77 ± 0.25§1.40

*Mice were immunized subcutaneously three times, 3 weeks apart with saline, GLA-SE (20 μg) adjuvant alone, or ID93 (8 μg) + adjuvant, or intradermally once with 5 × 104 BCG.

†Viable bacteria (CFU) expressed as log10 ± SD in the lungs and spleen of immunized animals (n = 7 per group) 3 or 4 weeks after a low-dose aerosol challenge with Mtb H37Rv or MDR-TB TN5904 strain, respectively. Data shown are representative of four independent experiments with H37Rv and one experiment with TN5904.

‡Reduction of viable bacteria in the lungs and spleen of immunized animals compared to saline controls.

§P < 0.01.

∥Statistical significance between saline and vaccine groups was determined by one-way ANOVA followed by Dunnett’s multiple comparison test.